{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:11:22Z","timestamp":1760058682856,"version":"build-2065373602"},"reference-count":31,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background: B-type natriuretic peptide (BNP) levels after ablation have been associated with a risk of arrhythmia recurrence (AR) after atrial fibrillation (AF) ablation. In addition, baseline BNP levels were also predictors of AR after AF ablation. However, previous studies have not been clear about whether sinus rhythm (SR) or AF was present at the time of BNP measurement. In this study, we investigated BNP levels in SR at 1,3 months after persistent AF ablation. Methods: We followed up 178 patients with persistent AF undergoing first-time arrhythmia ablation. BNP levels were measured before 1 and 3 months later after AF ablation in SR. The correlation between AR within 1 year after AF ablation and measured BNP levels was examined. Results: A total of 178 cases (81 males, mean age 69 (60, 74), mean CHA2DS2 Vasc score 2 (0, 4)) with persistent AF were included for ablation. BNP levels before AF ablation were not significantly different between AR and not AR patients. The BNP levels of AR patients were significantly elevated from 1 month to 3 months after the procedure compared with those without (\u221211.1 pg\/mL (\u221253, 5.7) vs. 17.8 pg\/mL (\u221258.3, 180.5), p &lt; 0.0001). Elevated BNP levels in SR after AF ablation were a significant predictor of AR. Conclusions: Elevated BNP levels in SR 3 months after AF ablation compared with BNP levels 1 month after persistent AF ablation might be a significant prognostic factor in AR.<\/jats:p>","DOI":"10.3390\/diseases13040126","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T20:38:26Z","timestamp":1745267906000},"page":"126","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Importance of B-Type Natriuretic Peptide Levels in Sinus Rhythm at 3 Months After Persistent Atrial Fibrillation Ablation"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8051-4105","authenticated-orcid":false,"given":"Jumpei","family":"Saito","sequence":"first","affiliation":[{"name":"Division of Cardiology, Showa University Northern Yokohama Hospital, Yokohama 224-0032, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Showa University Northern Yokohama Hospital, Yokohama 224-0032, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Koyanagi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Showa University Northern Yokohama Hospital, Yokohama 224-0032, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Yoshihiro","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Showa University Northern Yokohama Hospital, Yokohama 224-0032, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuma","family":"Gibo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Showa University Northern Yokohama Hospital, Yokohama 224-0032, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Usumoto","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Showa University Northern Yokohama Hospital, Yokohama 224-0032, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Igawa","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Showa University Northern Yokohama Hospital, Yokohama 224-0032, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Okabe","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Showa University Northern Yokohama Hospital, Yokohama 224-0032, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-0281","authenticated-orcid":false,"given":"Naoei","family":"Isomura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Showa University Northern Yokohama Hospital, Yokohama 224-0032, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Ochiai","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Showa University Northern Yokohama Hospital, Yokohama 224-0032, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.amjcard.2003.07.010","article-title":"Brain Natriuretic Peptide Is Elevated in Outpatients with Atrial Fibrillation","volume":"92","author":"Silvet","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"ref_2","first-page":"101132","article-title":"Atrial Fibrillation, Thromboembolic Risk, and the Potential Role of the Natriuretic Peptides, a Focus on BNP and NT-proBNP\u2014A Narrative Review","volume":"43","author":"Kerr","year":"2022","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.4070\/kcj.2019.0199","article-title":"Tachycardia Induced Cardiomyopathy","volume":"49","author":"Kim","year":"2019","journal-title":"Korean Circ. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/jama.2024.22451","article-title":"Atrial Fibrillation: A Review: A Review","volume":"333","author":"Ko","year":"2025","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.109.873265","article-title":"N-Terminal pro-B-Type Natriuretic Peptide Is a Major Predictor of the Development of Atrial Fibrillation: The Cardiovascular Health Study: The Cardiovascular Health Study","volume":"120","author":"Patton","year":"2009","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jacc.2005.05.057","article-title":"Impact of Atrial Fibrillation on the Diagnostic Performance of B-Type Natriuretic Peptide Concentration in Dyspneic Patients: An Analysis from the Breathing Not Properly Multinational Study","volume":"46","author":"Knudsen","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/FJC.0000000000001042","article-title":"Potential Biomarkers in Atrial Fibrillation: Insight into Their Clinical Significance: Insight into Their Clinical Significance","volume":"78","author":"Charafeddine","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S1071-9164(00)90010-1","article-title":"Atrium as a Source of Brain Natriuretic Polypeptide in Patients with Atrial Fibrillation","volume":"6","author":"Inoue","year":"2000","journal-title":"J. Card. Fail."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1161\/STROKEAHA.123.043302","article-title":"Biomarker, Imaging, and Clinical Factors Associated with Overt and Covert Stroke in Patients with Atrial Fibrillation","volume":"54","author":"Krisai","year":"2023","journal-title":"Stroke"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e025956","DOI":"10.1161\/JAHA.122.025956","article-title":"Clinical Outcomes of Rhythm Control Strategies for Asymptomatic Atrial Fibrillation According to the Quality-of-Life Score: The CODE-AF (Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation) Registry","volume":"11","author":"Kim","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1161\/CIRCULATIONAHA.110.007252","article-title":"Plasma B-Type Natriuretic Peptide Levels and Recurrent Arrhythmia after Successful Ablation of Lone Atrial Fibrillation","volume":"123","author":"Hussein","year":"2011","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10840-010-9540-2","article-title":"Predictive Value of B-Type Natriuretic Peptide Levels in Patients with Paroxysmal and Persistent Atrial Fibrillation Undergoing Pulmonary Vein Isolation","volume":"30","author":"Degener","year":"2011","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1253\/circj.CJ-23-0263","article-title":"Prognostic Importance of B-Type Natriuretic Peptide Level in Patients Undergoing Catheter Ablation for Atrial Fibrillation","volume":"87","author":"Kawaji","year":"2023","journal-title":"Circ. J."},{"key":"ref_14","first-page":"370","article-title":"B-Type Natriuretic Peptide, Disease Progression and Clinical Outcomes in Atrial Fibrillation","volume":"105","author":"Inohara","year":"2019","journal-title":"Heart"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/europace\/euw335","article-title":"Association of Pre-Ablation Level of Potential Blood Markers with Atrial Fibrillation Recurrence after Catheter Ablation: A Meta-Analysis","volume":"19","author":"Jiang","year":"2017","journal-title":"Europace"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00380-018-1267-5","article-title":"Pre-Ablation Levels of Brain Natriuretic Peptide Are Independently Associated with the Recurrence of Atrial Fibrillation after Radiofrequency Catheter Ablation in Patients with Nonvalvular Atrial Fibrillation","volume":"34","author":"Miake","year":"2019","journal-title":"Heart Vessels"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e33704","DOI":"10.1097\/MD.0000000000033704","article-title":"Natriuretic Peptides as Predictors for Atrial Fibrillation Recurrence after Catheter Ablation: A Meta-Analysis","volume":"102","author":"Yuan","year":"2023","journal-title":"Medicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.hrthm.2024.09.027","article-title":"Association between Postprocedural Echocardiographic and Laboratory Data and Clinical Outcomes in Patients with Preserved Ejection Fraction after Catheter Ablation for Atrial Fibrillation","volume":"22","author":"Sumiyoshi","year":"2025","journal-title":"Heart Rhythm"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Matsumoto, S., Matsunaga-Lee, Y., Ishimi, M., Ohnishi, M., Masunaga, N., Tachibana, K., and Takano, Y. (2021). Clinical Significance of B-Type Natriuretic Peptide Levels at 3 Months after Atrial Fibrillation Ablation. Diseases, 9.","DOI":"10.3390\/diseases9030049"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5594637","DOI":"10.1155\/2024\/5594637","article-title":"Relationship between Brain Natriuretic Peptide and Thromboembolic Events in Elderly Patients with Nonvalvular Atrial Fibrillation","volume":"2024","author":"Wang","year":"2024","journal-title":"Cardiol. Res. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13903","DOI":"10.1038\/s41598-023-41233-y","article-title":"Serum NT-proBNP Level for Predicting Functional Outcomes after Acute Ischemic Stroke","volume":"13","author":"Srisujikul","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1423147","DOI":"10.3389\/fcvm.2024.1423147","article-title":"Efficacy and Safety of Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis","volume":"11","author":"Chen","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.hrthm.2024.04.098","article-title":"Catheter Ablation for Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction Patients: A Meta-Analysis","volume":"21","author":"Pasqualotto","year":"2024","journal-title":"Heart Rhythm"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/europace\/eus162","article-title":"Type III Procollagen-N-Peptide as a Predictor of Persistent Atrial Fibrillation Recurrence after Cardioversion","volume":"14","author":"Kawamura","year":"2012","journal-title":"Europace"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.108.821306","article-title":"Atrial Fibrillation and Heart Failure: Treatment Considerations for a Dual Epidemic","volume":"119","author":"Anter","year":"2009","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jchf.2019.03.005","article-title":"Heart Failure and Atrial Fibrillation, like Fire and Fury","volume":"7","author":"Carlisle","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jacep.2021.10.009","article-title":"Assessing Interplay between Atrial Fibrillation and Heart Failure in Patients with Cardiac Implantable Electronic Devices","volume":"8","author":"Marine","year":"2022","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/eurheartj\/ehad798","article-title":"Oral Anticoagulation after Atrial Fibrillation Catheter Ablation: Benefits and Risks","volume":"45","author":"Kanaoka","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e32516","DOI":"10.1016\/j.heliyon.2024.e32516","article-title":"Real World Risk of Discontinuing Oral Anticoagulation after Successful Catheter Ablation for Atrial Fibrillation","volume":"10","author":"Fei","year":"2024","journal-title":"Heliyon"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/4\/126\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:18:58Z","timestamp":1760030338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/4\/126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["diseases13040126"],"URL":"https:\/\/doi.org\/10.3390\/diseases13040126","relation":{},"ISSN":["2079-9721"],"issn-type":[{"type":"electronic","value":"2079-9721"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}